•  
  •  
 

Abstract

Since March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has engulfed the world, including Indonesia, for nearly two years. SARS-CoV-2 has undergone several mutations during its evolution as a pathogen, resulting in various variants of global concern. Variants of this virus are suspected to impede the outbreak resolution and possibly causing the outbreak to spiral out of control. There is still considerable debate and research underway regarding the new SARS-CoV-2 variants. Rapid transmission mechanisms and widespread vaccination coverage have accelerated the virus’s mutation rate and resulted in numerous new variants. To date, this has resulted in the discovery of a new variant Omicron (B.1.1.529) in November 2021 in South Africa, which has since spread to 103 countries. Omicron is designated a Variant of Concern (VoC) due to its more powerful transmission than the previous variant. Although some information indicates that the symptoms associated with this variant are typically mild, the rapid transmission of Omicron can increase the next wave of COVID-19 cases. Additional research is required to determine transmissibility, pathogenesis, diagnosis, and proper management. As a result, we conducted an adjunct to studies on various COVID-19 mutations and variants until January 2022.

References

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. 2. World Health Organization. SARS-CoV-2 Variants [Internet]. Geneva: WHO; 2022 [cited 12 October 2021]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON305.3. World Health Organization. Coronavirus (COVID-19) Dashboard [Internet]. Geneva: WHO; 2022 [cited 12 October 2021]. Available from: https://covid19.who.int/.4. Worldometer. COVID live - Coronavirus Statistics - Worldometer [Internet]. Worldometers; 2022 [cited 30 January 2022]. Available from: https://www.worldometers.info/coronavirus/. 5. KawalCOVID19. Informasi terkini COVID-19 di Indonesia [Internet]. Kawalcovid19; 2022 [cited 30 March 2022]. Available from: https://kawalcovid19.id/. 6. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L; Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109-17. 7. Janik E, Niemcewicz M, Podogrocki M, Majsterek I, Bijak M. The emerging concern and interest SARS-CoV-2 variants. Pathogens. 2021;10(6):633.8. Groves DC, Rowland-Jones SL, Angyal A. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochem Biophys Res Commun. 2021;538:104-7. 9. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-27.10. Yewdell JW. Antigenic drift: understanding COVID-19. Immunity. 2021;54(12):2681-2687.11. World Health Organization. COVID-19 Weekly Epidemiological Update - 12 January 2021 [Internet]. Geneva: WHO; 2021 [cited 31 March 2022]. Available from: https://apps.who.int/iris/bitstream/handle/10665/338703/nCoV-weekly-sitrep12Jan21-eng.pdf?sequence=1&isAllowed=y.12. World Health Organization. Tracking SARS-CoV-2 variants [Internet]. World Health Organization. Geneva: WHO; 2021 [cited 2021 Oct 12]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/13. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24):2100509.14. Cedro-Tanda A, Gómez-Romero L, de Anda-Jauregui G, Garnica-López D, Alfaro-Mora Y, Sánchez-Xochipa S, et al. Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City. Viruses. 2022;14(3):545. 15. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions [Internet]. Atlanta, Georgia: Centers for Disease Control and Prevention; 2021 [cited 2022 Apr 1]. Available from: https://stacks.cdc.gov/view/cdc/10581716. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021 Dec;22(12):757-73. 17. Public Health Ontario. COVID-19 variant of concern Omicron [Internet]. Toronto, ON: Public Health Ontario; Nov 29, 2021 [cited 2022 March 20]. Available from: https://www.publichealthontario.ca/-/media/documents/ncov/voc/2021/11/covid-19-omicron-b11529-risk-assessment.pdf?sc_lang=en. 18. Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis. 2021;25(4):101606.19. Wink PL, Volpato FCZ, Monteiro FL, Willig JB, Zavascki AP, Barth AL, et al. First identification of SARS-CoV-2 lambda (C.37) variant in Southern Brazil. Infect Control Hosp Epidemiol. 2021 Sep 2:1-2. 20. Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Prada DA, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021;95:105038. 21. Network for Genomic Surveillance in South Africa (NGS-SA). SARS-CoV-2 Sequencing Update 1 December 2021 [Internet]. Network for Genomic Surveillance in South Africa (NGS-SA). 2021 [cited 2022 Apr 1]. Available from: https://www.nicd.ac.za/wp-content/uploads/2021/12/Update-of-SA-sequencing-data-from-GISAID-1-Dec-Final.pdf22. Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et al. Emergence of new SARS-CoV-2 variant of concern omicron (B.1.1.529) - highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268-72. 23. World Health Organization. COVID-19 Weekly Epidemiological Update Edition 69, published 7 December 2021 [Internet]. Geneva: World Health Organization; 2021 [cited 2022 Apr 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/350244/CoV-weekly-sitrep7Dec21-eng.pdf?sequence=1&isAllowed=y24. Hu J, Peng P, Cao X, Wu K, Chen J, Wang K, Tang N, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. 2022;19(2):293-95. 25. European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 24 March 2022 [Internet]. European Centre for Disease Prevention and Control; 2022 [cited 2022 Apr 1]. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern26. Global Initiative on Sharing All Influenza Data (GISAID). GISAID - submission tracker global [Internet]. Global Initiative on Sharing All Influenza Data (GISAID); 2022 [cited 2022 Mar 30]. Available from: https://www.gisaid.org/submission-tracker-global/27. European Centre for Disease Prevention and Control. Weekly epidemiological update: Omicron variant of concern (VOC) – week 1 (data as of 7 January 2022) EU/EEA [Internet]. European Centre for Disease Prevention and Control. 2022 [cited 2022 Apr 1]. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-1-data-7-january-202228. Satuan Tugas Penanganan COVID-19. Varian Omicron Terdeteksi di Indonesia [Internet]. Covid19.go.id. 2021 [cited 2022 Apr 1]. Available from: https://covid19.go.id/p/masyarakat-umum/varian-omicron-terdeteksi-di-indonesia29. Robinson J, Banerjee I, Leclézio A, Sathian B. COVID-19 and mutations a threat level assessment. Nepal J Epidemiol. 2021;11(1):983-7.30. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2022 Feb 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.31. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24.32. Grubaugh ND, Petrone ME, Holmes EC. We shouldn’t worry when a virus mutates during disease outbreaks. Nat Microbiol. 2020 Apr;5(4):529-30.33. Otto SP, Day T, Arino J, Colijn C, Dushoff J, Li M, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021;31(14):R918-29.34. Baj A, Novazzi F, Drago Ferrante F, Genoni A, Tettamanzi E, Catanoso G, Dalla Gasperina D, Dentali F, Focosi D, Maggi F. Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy. Emerg Microbes Infect. 2021;10(1):2010-5. 35. Lacobucci G. Covid-19: Single vaccine dose is 33% effective against variant from India, data show. BMJ. 2021;373:n1346.36. Jogalekar MP, Veerabathini A, Gangadaran P. SARS-CoV-2 variants: A double-edged sword? Exp Biol Med (Maywood). 2021;246(15):1721-6.37. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-5.38. Shrestha LB, Tedla N, Bull RA. Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants. Front Immunol. 2021;12:752003.39. Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K. Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virol J. 2021;18(1):166.40. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2022;94(4):1641-9. 41. Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) Variant [Internet]. Atlanta, Gerogia: Centers for Disease Control and Prevention; 2021 [cited 2022 Apr 1]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html42. Poudel S, Ishak A, Perez-Fernandez J, Garcia E, León-Figueroa DA, Romaní L, et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts - What is known so far? Travel Med Infect Dis. 2022;45:102234.43. Fratev F. The High Transmission of SARS-CoV-2 Omicron (B.1.1.529) Variant is Not Only Due to Its hACE2 binding: A Free Energy of Perturbation Study. bioRxiv [Preprint]. 2021 [cited 31 March 2022];. Available from: https://www.biorxiv.org/content/10.1101/2021.12.04.471246v1 44. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI J. 2020;19:410-17. 45. Moeed M, Azam I, Naaz F, Salman M. Social Determinants of Anthropometric Outcomes: A Differentiation and Correlation Study in South Indian Children aged 8 – 12 years. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH [Internet]. 2017 [cited 31 March 2022];6(10):337-340. Available from: https://www.worldwidejournals.com/international-journal-of-scientific-research-(IJSR)/fileview.php?val=October_2017_1506781302__115.pdf46. Zhang J, Xiao T, Cai Y, Chen B. Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021 Oct;50:173-82.47. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci. 2020;257:118056.48. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-92. 49. Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena L, et al. Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. J Med Virol. 2021 Dec;93(12):6845-9. 50. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. Geneva: WHO; 2022 [cited 31 March 2022]. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern51. New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). Brief note of the extraordinary meeting of NERVTAG subgroup on SARS-CoV-2 variant B.1.1.529, 25 November 2021 [Internet]. GOV.UK; 2022 [cited 31 March 2022]. Available from: https://www.gov.uk/government/publications/nervtag-brief-note-of-the-extraordinary-meeting-of-nervtag-subgroup-on-sars-cov-2-variant-b11529-25-november-2021. 52. Moore T. COVID-19: Omicron causing up to 1,000 infections a day in UK - many more than official figures suggest, leading scientist says [Internet]. Sky News. 2021 [cited 31 March 2022]. Available from: https://news.sky.com/story/covid-19-omicron-causing-up-to-1-000-infections-a-day-many-more-than-official-figures-suggest-leading-scientist-says-1248864053. Gu H, Krishnan P, Ng DYM, Chang LDJ, Liu GYZ, Cheng SSM, et al. Probable transmission of SARS-CoV-2 Omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect 54. UK Health Security Agency. Risk assessment for SARS-CoV-2 variant: Omicron VOC-21NOV-01 (B.1.1.529) [Internet]. UK Health Security Agency; 2022 [cited 31 March 2022]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046614/12-january-2022-risk-assessment-SARS-Omicron_VOC-21NOV-01_B.1.1.529.pdf. 55. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. UK Health Security Agency; 2021 [cited 2022 Apr 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf56. UK Department of Health and Social Care. Oral statement on the COVID-19 pandemic [Internet]. UK Department of Health and Social Care; 2021 [cited 2022 Apr 1]. Available from: https://www.gov.uk/government/speeches/oral-statement-on-the-covid-19-pandemic 57. Genovese L, Zaccaria M, Farzan M, Johnson W, Momeni B. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. bioRxiv [Preprint]. 2021 [cited 31 March 2022];. Available from: https://www.biorxiv.org/content/10.1101/2021.12.01.470748v1. 58. Shah M, Woo HG. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. Front Immunol. 2022;12:830527. 59. Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Invest. 2021;131(5):e145476.60. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, Ku Z, et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv [Preprint]. 2021;2021:434499. 61. Kontopodis E, Pierros V, Stravopodis DJ, Tsangaris GT. Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through the Analysis of Spike Protein-Specific Core Unique Peptides. Vaccines (Basel). 2022;10(3):357. 62. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.63. Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35(13):109292. 64. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol. 2021 Jul;6(7):899-909. 65. Winstone H, Lista MJ, Reid AC, Bouton C, Pickering S, Galao RP, et al. The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. J Virol. 2021;95(9):e02422-20. 66. McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, et al. Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. Med (N Y). 2022 Mar 17. 67. Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021;26(50):2101146. 68. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;15:eabn4947. 69. Gao SJ, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol. 2022;94(4):1255-6.70. Daria S, Bhuiyan MA, Islam MR. Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions. J Med Virol. 2022;94(4):1267-8. 71. CBC News. First case of omicron COVID-19 variant confirmed in Alberta, Hinshaw says [Internet]. CBC News; 2021 [cited 2022 Apr 2]. Available from: https://www.cbc.ca/news/canada/edmonton/deena-hinshaw-covid-19-alberta-1.626827672. Brooks L. Scottish Omicron cases all linked to one ‘private event’, says Sturgeon [Internet]. The Guardian; 2021 [cited 2022 Apr 2]. Available from: https://www.theguardian.com/uk-news/2021/nov/30/scottish-omicron-covid-variant-cases-linked-private-event-says-sturgeon73. Centers for Disease Control and Prevention. First Confirmed Case of Omicron Variant Detected in the United States [Internet]. Centers for Disease Control and Prevention Newsroom. 2021 [cited 2022 Apr 2]. Available from: https://www.cdc.gov/media/releases/2021/s1201-omicron-variant.html74. Abdullah F. Tshwane District Omicron variant patient profile - early features [Internet]. South African Medical Research Council; 2022 [cited 30 March 2022]. Available from: https://www.samrc.ac.za/news/tshwane-district-omicron-variant-patient-profile-early-features. 75. World Health Organization. COVID-19 weekly epidemiological update edition 76, published 25 January 2022 [Internet]. Geneva: WHO; 2022 [cited 31 March 2022]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20220125_weekly_epi_update_76.pdf. 76. European Centre for Disease Prevention and Control. Threat Assessment Brief: Implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA - first update [Internet]. European Centre for Disease Prevention and Control; 2021 [cited 2022 Apr 2]. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-threat-assessment-spread-omicron-first-update77. World Health Organization. Update on Omicron [Internet]. Geneva: World Health Organization; 2021 [cited 2022 Apr 2]. Available from: https://www.who.int/news/item/28-11-2021-update-on-omicron78. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. Morb Mortal Wkly Rep. 2021;70(50):1731-4. 79. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021. Emerg Infect Dis. 2021;27(12):3020-9.80. European Centre for Disease Prevention and Control. Communicable disease threats report, 28 November-4 December 2021, week 48 [Internet]. European Centre for Disease Prevention and Control; 2021 [cited 31 March 2022]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week%2048-2021.pdf. 81. Vousden N, Ramakrishnan R, Bunch K, et al. Severity of maternal infection and perinatal outcomes during periods of SARS-CoV-2 wildtype, alpha, and delta variant dominance in the UK: prospective cohort study. BMJ Med. 2022;1(1):e000053.82. Gunadi G, Hakim MS, Wibawa H, Marcellus M, Setiawaty V, Slamet S, et al. Is the Infection of the SARS-CoV-2 Delta Variant Associated With the Outcomes of COVID-19 Patients? Front Med (Lausanne). 2021;8:780611. 83. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-65. 84. Auvigne V, Vaux S, Strat Y le, Schaeffer J, Fournier L, Montagnat C, et al. Serious hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants: an exposed-unexposed cohort study in December 2021 from the COVID-19 surveillance databases in France. medRxiv. 2022;2022:22269952. 85. Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27(4):2200077.86. Cryer MJ, Farhan S, Kaufmann CC, Jäger B, Garg A, Krishnan P, et al. Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review. Clin Appl Thromb Hemost. 2022;28:10760296221074353.87. Rosen RJ. Thrombotic complications in critically ill patients with COVID 19. Thromb Res. 2020;191:56. 88. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. 89. Serban D, Tribus LC, Vancea G, Stoian AP, Dascalu AM, Suceveanu AI, et al. Acute Mesenteric Ischemia in COVID-19 Patients. J Clin Med. 2021;11(1):200.90. Galyfos G, Sianou A, Frountzas M, Vasilios K, Vouros D, Theodoropoulos C, et al. Acute limb ischemia among patients with COVID-19 infection. J Vasc Surg. 2022;75(1):326-42.91. Hemingway J, Emanuels D, Aarabi S, Quiroga E, Tran N, Starnes B, et al. Safety of transfer, type of procedure, and factors predictive of limb salvage in a modern series of acute limb ischemia. J Vasc Surg. 2019;69(4):1174-1179. 92. Piffaretti G, Angrisano A, Franchin M, Ferrario M, Rivolta N, Bacuzzi A, et al. Risk factors analysis of thromboembolectomy for acute thromboembolic lower extremity ischemia in native arteries. J Cardiovasc Surg (Torino). 2018;59(6):810-6.93. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, et al. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Front Cardiovasc Med. 2021;8:767074. 94. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738-44.95. Phan T, Boes S, McCullough M, Gribschaw J, Marsh J, Harrison LH, et al. Development of a One-Step Qualitative RT-PCR Assay to Detect the SARS-CoV-2 Omicron (B.1.1.529) Variant in Respiratory Specimens. J Clin Microbiol. 2022;60(3):e0002422.96. Greninger AL, Dien Bard J, Colgrove RC, Graf EH, Hanson KE, Hayden MK, et al. Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document. Clin Infect Dis. 2021;3:ciab761.97. Saxena SK, Kumar S, Baxi P, Srivastava N, Puri B, Ratho RK. Chasing COVID-19 through SARS-CoV-2 spike glycoprotein. Virusdisease. 2020;31(4):1-9.98. Mani Mishra P, Uversky VN, Nandi CK. Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2. Med Hypotheses. 2020;140:109790. 99. National Institutes of Health. Therapeutic management of nonhospitalized adults with COVID-19 [Internet]. National Institutes of Health COVID-19 Treatment Guidelines; 2022 [cited 31 March 2022]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/100. Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem. 2016;59(14):6595-628. 101. Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-93. 102. The U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of Baricitinib [Internet]. Eli Lilly and Company; 2021 [cited 2022 Apr 2]. p. 1–13. Available from: https://www.fda.gov/media/143823/download 103. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine. 2021;385(21):1941–50. 104. The U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of The Pfizer-Biontech COVID-19 vaccine to prevent Coronavirus disease 2019 (COVID-19) [Internet]. Pfizer-BioNTech; 2020 [cited 2022 Apr 2]. p. 1–29. Available from: https://lalinks.org/linksweb/docs/fact_sheet_for_hcp_administering_vaccine.pdf 105. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-15. 106. Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021;224(3):415-9.107. Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, Höbartner C, Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-6. 108. FA The U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for LagevrioTM(molnupiravir) Capsules [Internet]. Merck & Co., Inc; 2022 [cited 2022 Apr 2]. p. 1–19. Available from: https://www.fda.gov/media/155054/download 109. Kim TH. South Korea confirms first five cases of omicron variant [Internet]. AP NEWS. 2022 [cited 30 March 2022]. Available from: https://apnews.com/article/coronavirus-pandemic-technology-health-pandemics-seoul-2a6fe0aea53aae692cd863a01638b0ce.110. Naidoo P, Cele S. Scientists detect new COVID-19 variant in South Africa with ‘very unusual’ mutations [Internet]. National Post; 2021 [cited 2022 Apr 2]. Available from: https://nationalpost.com/news/world/scientists-detect-a-new-variant-in-south-africa-with-very-unusual-mutations 111. GAVI. What do we know about the new B.1.1.529 coronavirus variant and should we be worried? [Internet]. Gavi, The Vaccine Alliance; 2022 [cited 30 March 2022]. Available from: https://www.gavi.org/vaccineswork/what-we-know-about-new-b11529-coronavirus-variant-so-far. 112. The Canadian Press. Alberta’s chief medical officer says most of 11 Omicron COVID-19 cases were vaccinated [Internet]. The Globe and Mail; 2021 [cited 2022 Apr 2]. Available from: https://www.theglobeandmail.com/canada/article-albertas-chief-medical-officer-says-most-of-11-omicron-covid-19-cases/ 113. Corum J, Zimmer C. Tracking Omicron and Other Coronavirus Variants [Internet]. The New York Times; 2022 [cited 2022 Apr 2]. Available from: https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html114. Mulcahy R. Harvard epidemiologist awaits clearer picture on Omicron [Internet]. Harvard Gazette. 2021 [cited 30 March 2022]. Available from: https://news.harvard.edu/gazette/story/2021/11/harvard-epidemiologist-awaits-clearer-picture-on-omicron/.115. Janssen. Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant [Internet]. Janssen; 2021 [cited 30 March 2022]. Available from: https://www.janssen.com/johnson-johnson-evaluate-its-covid-19-vaccine-against-new-omicron-covid-19-variant.116. Business Wire. Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant [Internet]. Business Wire; 2021 [cited 30 March 2022]. Available from: https://www.businesswire.com/news/home/20211126005595/en/Moderna-Announces-Strategy-to-Address-Omicron-B.1.1.529-SARS-CoV-2-Variant.117. Reuters. BioNTech starts work on Omicron-specific vaccine [Internet]. Reuters; 2021 [cited 30 March 2022]. Available from: https://www.reuters.com/markets/stocks/biontech-starts-work-omicron-specific-vaccine-2021-11-29/.118. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv [Preprint]. 2021;2021:12. 119. Ford C, Jacob Machado D, Janies D. Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions. Front Virol. 2022;2:830202. 120. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;2022:NEJMoa2119451.121. UK Department of Health and Social Care. All adults to be offered COVID-19 boosters by end of January [Internet]. UK Department of Health and Social Care; 2021 [cited 2022 Apr 2]. Available from: https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-of-january122. The Local France. Calendar: when do France’s new Covid measures come into force? [Internet]. The Local France; 2021 [cited 30 March 2022]. Available from: https://www.thelocal.fr/20211125/calendar-when-do-frances-new-covid-measures-come-into-force/.123. Marshall E. France tightens rules for tourists as Omicron causes panic across Europe [Internet]. Express.co.uk. 2021 [cited 30 March 2022]. Available from: https://www.express.co.uk/travel/articles/1529112/france-british-tourists-travel-rules-covid-pass-booster-omicron. 124. The Finnish Institute for Health and Welfare. THL recommends that third coronavirus vaccine doses be offered 5 to 6 months after the second dose to all those aged 18 or over [Internet]. The Finnish Institute for Health and Welfare. 2021 [cited 2022 Apr 2]. Available from: https://thl.fi/en/web/thlfi-en/-/thl-recommends-that-third-coronavirus-vaccine-doses-be-offered-5-to-6-months-after-the-second-dose-to-all-those-aged-18-or-over125. Efrati I. Israel confirms 21 omicron cases; expert panel to discuss fourth COVID shot [Internet]. Haaretz; 2021 [cited 30 March 2022]. Available from: https://www.haaretz.com/israel-news/israel-confirms-21-omicron-cases-expert-panel-to-discuss-fourth-covid-shot-1.10444016. 126. Reuters. France’s health regulator backs vaccination for vulnerable children aged 5-11 [Internet]. Reuters; 2021 [cited 2022 Apr 2]. Available from: https://www.reuters.com/world/europe/frances-health-regulator-backs-vaccination-vulnerable-children-aged-5-11-2021-11-30/127. Lehto E. Finland to limit children’s COVID-19 vaccines to high-risk households [Internet]. Reuters; 2021 [cited 2022 Apr 2]. Available from: https://www.reuters.com/world/europe/finland-limit-childrens-covid-19-vaccines-high-risk-households-2021-12-02/ 128. Danish Health Authority. Booster vaccination against COVID-19 [Internet]. Danish Health Authority; 2022 [cited 2022 Apr 2]. Available from: https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19/booster-vaccination129. Fox M. All vaccinated adults should get a Covid-19 booster shot because of the Omicron variant, CDC says [Internet]. CNN; 2021 [cited 2022 Apr 2]. Available from: https://edition.cnn.com/2021/11/29/health/cdc-booster-guidance-omicron/index.html

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.